Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

119 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment.
Solimando AG, Da Vià MC, Cicco S, Leone P, Di Lernia G, Giannico D, Desantis V, Frassanito MA, Morizio A, Delgado Tascon J, Melaccio A, Saltarella I, Ranieri G, Ria R, Rasche L, Kortüm KM, Beilhack A, Racanelli V, Vacca A, Einsele H. Solimando AG, et al. J Clin Med. 2019 Jul 9;8(7):997. doi: 10.3390/jcm8070997. J Clin Med. 2019. PMID: 31323969 Free PMC article. Review.
Editorial: Angiogenesis blockade for the treatment of gastrointestinal cancer.
Passardi A, Bittoni A, Bai Z, Zhang Z, Sier C, He Y, Shahini E, Solimando AG. Passardi A, et al. Among authors: solimando ag. Front Oncol. 2023 Feb 1;13:1147849. doi: 10.3389/fonc.2023.1147849. eCollection 2023. Front Oncol. 2023. PMID: 36816979 Free PMC article. No abstract available.
Novel targeting of phospho-cMET overcomes drug resistance and induces antitumor activity in multiple myeloma.
Moschetta M, Basile A, Ferrucci A, Frassanito MA, Rao L, Ria R, Solimando AG, Giuliani N, Boccarelli A, Fumarola F, Coluccia M, Rossini B, Ruggieri S, Nico B, Maiorano E, Ribatti D, Roccaro AM, Vacca A. Moschetta M, et al. Among authors: solimando ag. Clin Cancer Res. 2013 Aug 15;19(16):4371-82. doi: 10.1158/1078-0432.CCR-13-0039. Epub 2013 Jun 26. Clin Cancer Res. 2013. PMID: 23804425
A HGF/cMET autocrine loop is operative in multiple myeloma bone marrow endothelial cells and may represent a novel therapeutic target.
Ferrucci A, Moschetta M, Frassanito MA, Berardi S, Catacchio I, Ria R, Racanelli V, Caivano A, Solimando AG, Vergara D, Maffia M, Latorre D, Rizzello A, Zito A, Ditonno P, Maiorano E, Ribatti D, Vacca A. Ferrucci A, et al. Among authors: solimando ag. Clin Cancer Res. 2014 Nov 15;20(22):5796-807. doi: 10.1158/1078-0432.CCR-14-0847. Epub 2014 Sep 11. Clin Cancer Res. 2014. PMID: 25212607
Microenvironment drug resistance in multiple myeloma: emerging new players.
Di Marzo L, Desantis V, Solimando AG, Ruggieri S, Annese T, Nico B, Fumarulo R, Vacca A, Frassanito MA. Di Marzo L, et al. Among authors: solimando ag. Oncotarget. 2016 Sep 13;7(37):60698-60711. doi: 10.18632/oncotarget.10849. Oncotarget. 2016. PMID: 27474171 Free PMC article. Review.
JAM-A as a prognostic factor and new therapeutic target in multiple myeloma.
Solimando AG, Brandl A, Mattenheimer K, Graf C, Ritz M, Ruckdeschel A, Stühmer T, Mokhtari Z, Rudelius M, Dotterweich J, Bittrich M, Desantis V, Ebert R, Trerotoli P, Frassanito MA, Rosenwald A, Vacca A, Einsele H, Jakob F, Beilhack A. Solimando AG, et al. Leukemia. 2018 Mar;32(3):736-743. doi: 10.1038/leu.2017.287. Epub 2017 Sep 28. Leukemia. 2018. PMID: 29064484 Free PMC article.
119 results